A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Key claim: A Phase I/II trial will test trametinib plus azacitidine in newly diagnosed lower-risk JMML, adding fludarabine and cytarabine for high-risk disease, to assess safety and efficacy.
Abstract
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.
Why this matters
JMML is the paradigmatic RAS-MAPK–driven pediatric MDS/MPN overlap disease, yet dedicated prospective therapeutic evidence has been dominated by transplant-focused strategies. A risk-stratified Phase I/II combining MEK inhibition (trametinib) with hypomethylating therapy — intensified with fludarabine/cytarabine for high-risk disease — directly tests the central biologic hypothesis of JMML and could establish a non-transplant or bridge-to-transplant backbone in a subtype where such options have been scarce.